Advertisement.

GRCL Projected Dividend Yield

ADR (Sponsored)/Gracell Biotechnologies Inc ( NASDAQ : GRCL )

Gracell Biotechnologies is a holding company. Through its subsidiaries, Co. engages in discovering and developing cell therapies to resolve industry challenges and fulfill unmet medical needs in the treatment of cancer. Co.'s product candidates include: GC012F is a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate for the treatment of MM; GC019F is a FasTCAR-enabled CD19-directed autologous CAR-T product candidate for the treatment of adult B-ALL; GC027 is a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate for the treatment of adult T-ALL; and GC007g is a donor-derived CD19-directed allogeneic CAR-T cell therapy for the treatment of r/r B-ALL.

20 YEAR PERFORMANCE RESULTS

GRCL Dividend History Detail
GRCL Dividend News
GRCL Competitors News

# of Shares: 0

Closing Price: 10.25

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000